Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity

Linda Spiegelberg, Stefan J. van Hoof, Rianne Biemans, Natasja G. Lieuwes, Damienne Marcus, Raymon Niemans, Jan Theys, Ala Yaromina, Philippe Lambin, Frank Verhaegen, Ludwig J. Dubois*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)247-255
Number of pages9
JournalRadiotherapy and Oncology
Volume141
DOIs
Publication statusPublished - Dec 2019

Keywords

  • TH-302
  • Radiotherapy
  • Esophageal cancer
  • Short-term gut toxicity
  • Long-term lung fibrosis
  • Therapeutic index
  • HYPOXIA-ACTIVATED PRODRUG
  • TOTAL-BODY IRRADIATION
  • PRO-DRUG TH-302
  • TUMOR HYPOXIA
  • PHASE-I
  • CANCER
  • RADIOTHERAPY
  • COMBINATION
  • DOXORUBICIN
  • INJURY

Cite this